Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | UBE2N | P61088 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.66 |
| ▸ | HTR6 | P50406 | 7/20 | 0.61 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.55 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.54 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | KLK7 | P49862 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29460860 | 1.00 | KDM4E (0.68) | KDM4EUBE2NL3MBTL1HTR6AKR1C3 | |
| SCHEMBL1891254 | 0.88 | KDM4E (0.56) | KDM4EUBE2NL3MBTL1HTR6AKR1C3 | |
| SCHEMBL1996382 | 0.87 | HTR6 (0.64) | L3MBTL1HTR6AKR1C3AKR1C1CA2 | |
| SCHEMBL29651100 | 0.87 | HTR6 (0.64) | L3MBTL1HTR6AKR1C3AKR1C1CA2 | |
| SCHEMBL5551520 | 0.85 | L3MBTL1 (0.63) | KDM4EUBE2NL3MBTL1HTR6AKR1C3 | |
| SCHEMBL1894157 | 0.85 | CA1 (0.54) | KDM4EUBE2NL3MBTL1HTR6ALOX5 | |
| SCHEMBL3615171 | 0.84 | HTR6 (0.78) | KDM4EUBE2NL3MBTL1HTR6ALOX5 | |
| SCHEMBL12449919 | 0.83 | HTR6 (0.52) | KDM4EUBE2NL3MBTL1HTR6ALK | |
| SCHEMBL13257975 | 0.83 | KDM4E (0.51) | KDM4EUBE2NL3MBTL1HTR6ALK | |
| SCHEMBL30295156 | 0.83 | CA2 (0.49) | KDM4EUBE2NL3MBTL1HTR6AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466813-B2 | PRC1 inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4155293-B1 | PRC1 INHIBITORS AND METHODS OF TREATMENT THEREWITH | UNIV MICHIGAN REGENTS (US) | 2025-07-30 | — | — | EP | disclosed |
| CN-112533581-B | PRC1 inhibitors and methods of treatment therewith | 密歇根大学董事会 | 2024-08-30 | — | — | CN | disclosed |
| CN-115925686-B | MERIDIANIN derivatives, lewis acid-promoted coupling synthesis method and application thereof | 贵州医科大学 | 2024-07-30 | — | — | CN | disclosed |
| EP-3813784-B1 | PRC1 INHIBITORS AND PRC1 INHIBITORS FOR USE IN METHODS OF TREATMENT THEREWITH | UNIV MICHIGAN REGENTS (US) | 2024-01-10 | — | — | EP | disclosed |
| US-20230303573-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | Grünenthal GmbH (DE) | 2023-09-28 | — | — | US | disclosed |
| US-20230118233-A1 | PRC1 INHIBITORS AND METHODS OF TREATMENT THEREWITH | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-04-20 | — | — | US | disclosed |
| CN-115925686-A | Meridianin derivatives, coupling synthesis method and application thereof promoted by Lewis acid | 贵州医科大学 | 2023-04-07 | — | — | CN | disclosed |
| US-11319302-B2 | PRC1 inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-05-03 | — | — | US | disclosed |
| WO-2022078971-A1 | NOVEL COMPOUNDS | AC IMMUNE SA (CH) | 2022-04-21 | — | — | WO | disclosed |
| US-7750145-B2 | 1-substituted-3-β-D-glucopyranosylated nitrogenous hetero-cyclic compounds and medicines containing the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-07-06 | — | — | US | disclosed |
| US-7750145-B2 | 1-substituted-3-β-D-glucopyranosylated nitrogenous hetero-cyclic compounds and medicines containing the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-07-06 | — | — | US | disclosed |
| US-7750145-B2 | 1-substituted-3-β-D-glucopyranosylated nitrogenous hetero-cyclic compounds and medicines containing the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-07-06 | — | — | US | disclosed |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-20090074738-A1 | 1-SUBSTITUTED-3-BETA-D-GLUCOPYRANOSYLATED NITROGENOUS HETERO-CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-03-19 | — | — | US | disclosed |
| US-20090074738-A1 | 1-SUBSTITUTED-3-BETA-D-GLUCOPYRANOSYLATED NITROGENOUS HETERO-CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-03-19 | — | — | US | disclosed |
| US-20090074738-A1 | 1-SUBSTITUTED-3-BETA-D-GLUCOPYRANOSYLATED NITROGENOUS HETERO-CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-03-19 | — | — | US | disclosed |
| EP-1813611-A1 | 1-SUBSTITUTED-3- BETA-D-GLUCOPYRANOSYLATED NITROGENOUS HETERO- CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-08-01 | — | — | EP | disclosed |
| US-6642228-B1 | Treating ocular tension, carcinoma, sarcoma, tumentia, circulatory disease, or hypertension | TORAY INDUSTRIES, INC. (JP) | 2003-11-04 | — | — | US | disclosed |
| EP-1106605-A1 | ALPHA1B-ADRENERGIC RECEPTOR ANTAGONISTS | TORAY INDUSTRIES, INC. (JP) | 2001-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | JAK3, JAK2, JAK1 | KDM4E 702/4885UBE2N 1800/4885L3MBTL1 3573/4885 |
| US-12466813-B2 | PRC1 inhibitors and methods of treatment therewith | BMI1, EZH2, CBX3 | KDM4E 154/4885UBE2N 1913/4885L3MBTL1 326/4885 |
| US-20230303573-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, OPRL1 | KDM4E 2919/4885UBE2N 1646/4885L3MBTL1 3887/4885 |
| US-11319302-B2 | PRC1 inhibitors and methods of treatment therewith | BMI1, EZH2, CBX3 | KDM4E 154/4885UBE2N 1913/4885L3MBTL1 326/4885 |
| US-20090074738-A1 | 1-SUBSTITUTED-3-BETA-D-GLUCOPYRANOSYLATED NITROGENOUS HETERO-CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME | SLC5A1, SLC5A2, UGGT1 | KDM4E 3629/4885UBE2N 2909/4885L3MBTL1 1346/4885 |
| US-20230118233-A1 | PRC1 INHIBITORS AND METHODS OF TREATMENT THEREWITH | BMI1, EZH2, CBX3 | KDM4E 154/4885UBE2N 1913/4885L3MBTL1 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.